Kimberly  Park net worth and biography

Kimberly Park Biography and Net Worth

Kimberly Park has served as a member of our Board since September 2019. She was Global Vice President of Customer Strategy and Innovation at Merck & Co. from 2014 to 2018 and also held global and U.S. leadership roles at Merck from 1997 to 2005, including U.S. Vice President of Managed Care Marketing. From 2005 to 2014, Ms. Park served in senior leadership roles at Johnson and Johnson, including Founding Partner and Global Vice President of Janssen Healthcare Innovation from 2010 to 2014 and U.S. Vice President of Primary Care Sales and Marketing of Janssen Pharmaceuticals from 2005 to 2010. Prior to joining Merck, Ms. Park held U.S. and global commercial leadership positions at GlaxoSmithKline plc. Ms. Park has served on the board of directors of Besser Company, a manufacturer of equipment for the building materials industry, since 2018, and TechEtch, a precision manufacturing company that supplies medical device and aerospace industries, since January 2021. She also serves as a trustee for two private foundations and is a mentor for Philadelphia Alliance of Capital and Technology. Ms. Park co-founded and serves as Secretary of the Aplex Community Center, a new non-profit organization that provides Northeast Michigan with a multi-use facility for residents and visitors. Ms. Park received her B.A. in International Business from the University of Michigan.

What is Kimberly Park's net worth?

The estimated net worth of Kimberly Park is at least $3.42 million as of August 26th, 2026. Ms. Park owns 30,000 shares of Corcept Therapeutics stock worth more than $3,416,400 as of August 31st. This net worth approximation does not reflect any other assets that Ms. Park may own. Learn More about Kimberly Park's net worth.

How do I contact Kimberly Park?

The corporate mailing address for Ms. Park and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Kimberly Park's contact information.

Has Kimberly Park been buying or selling shares of Corcept Therapeutics?

In the last ninety days, Kimberly Park has sold $3,270,246.75 in shares of Corcept Therapeutics stock. Most recently, Kimberly Park sold 26,685 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $122.55, for a transaction totalling $3,270,246.75. Following the completion of the sale, the director now directly owns 30,000 shares of the company's stock, valued at $3,676,500. Learn More on Kimberly Park's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Atabak Mokari (CFO), Kimberly Park (Director), Gary Robb (CFO), Daniel Swisher, Jr. (Director), and James Wilson (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, Corcept Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $3,314,000.00. In the last year, insiders at the biotechnology company sold shares 48 times. They sold a total of 1,052,884 shares worth more than $88,623,896.31. The most recent insider tranaction occured on August, 26th when Director Kimberly Park sold 26,685 shares worth more than $3,270,246.75. Insiders at Corcept Therapeutics own 20.7% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 8/26/2026.

Kimberly Park Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2026Sell26,685$122.55$3,270,246.7530,000View SEC Filing Icon  
See Full Table

Kimberly Park Buying and Selling Activity at Corcept Therapeutics

This chart shows Kimberly Park's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $111.97
Low: $111.25
High: $114.53

50 Day Range

MA: $101.17
Low: $79.71
High: $123.57

2 Week Range

Now: $111.97
Low: $28.66
High: $126.38

Volume

86,068 shs

Average Volume

1,508,243 shs

Market Capitalization

$12.10 billion

P/E Ratio

267.00

Dividend Yield

N/A

Beta

0.45